RNS Number : 9610D
Shield Therapeutics PLC
20 November 2026

Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

Block Listing Application

London, UK, 20 November 2026 – Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company focused on iron deficiency, hereby provides notification that application has been made to the London Stock Exchange for admission to trading on AIM of 10,000,000 new ordinary shares of 1.5p each ("Ordinary Shares") under an extension to its existing block listing in respect of its Retention and Performance Share Plan.

On exercise of the options, the new Ordinary Shares will be credited as fully paid which will rank pari passu with the existing Common Shares in issue.

It is expected that such admission will become effective on or around 25 November 2026.

For further information please contact:

Shield Therapeutics plc
Anders Lundstrom, CEO
Michael Jensen, CFO
Stephanie Hicks, Investor Relations
https://shieldtherapeutics.com/link/rJjEpr

www.shieldtherapeutics.com
+44 (0) 191 511 8500
Investorrelations@shieldtx.com

Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel

+44 (0)20 7418 8900

Joint Broker
Cavendish Ltd
Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward

+44 (0)20 7220 0500

About Iron Deficiency and ACCRUFeR® /FeRACCRU®
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for children and adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the #1 branded prescription oral iron in the US market today (*data source - IQVIA Xponent PlanTrak).

ACCRUFeR® /FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for patients suffering from iron deficiency, with or without anemia. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR® /FeRACCRU®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.

About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR® /FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients

suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFeR® in the U.S. to include pediatric patients 10 years of age and older. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK and European Union by Norgine B.V., to include pediatric patients 12 years of age and older and also have marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement in Canada by Kye Pharmaceuticals Inc, Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR®/FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.

ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.
ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFFFFILLLALIR